Rage Biotech Pty Ltd

Rage Biotech logo

RAGE Biotech is developing novel therapies to address the Receptor for Advanced Glycation End-products (RAGE), which is a key, difficult-to-treat target in chronic inflammatory diseases. Their therapies can increase naturally occurring anti-inflammatory spliceforms and block pro-inflammatory signalling, which will improve the lives of people with chronic inflammation around the world.

Year established:  2020
Lead Researcher & Founder: Merlin Thomas,
Co-founders: Steve Wilton, Kevin Pfleger
CEO: Chris Wraight
Website: ragebiotech.com